Rezultati - Faramarz Ismail‐Beigi
- Showing 1 - 20 results of 50
- Go to Next Page
-
1
Clinical Implications of the ACCORD Trial od Saul Genuth, Faramarz Ismail‐Beigi
Izdano 2011Revisão -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials od Sepehr Gohari, Faramarz Ismail‐Beigi, Mahsa Mahjani, Saeed Ghobadi, Alireza Jafari, Hassan Ahangar, Sheida Gohari
Izdano 2023Revisão -
18
Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial od Hoda Taheri, Mojtaba Malek, Faramarz Ismail‐Beigi, Farhad Zamani, Masoudreza Sohrabi, Mohammad Reza Babaei, Mohammad E. Khamseh
Izdano 2020Artigo -
19
-
20
Iskalna orodja:
Sorodne teme
Endocrinology
Medicine
Internal medicine
Diabetes mellitus
Type 2 diabetes
Insulin
Biology
Chemistry
Intensive care medicine
Biochemistry
Insulin resistance
Randomized controlled trial
Confidence interval
Disease
Glycemic
Gene
Alternative medicine
Hazard ratio
Hypoglycemia
Organic chemistry
Pathology
Placebo
Cardiology
Cell biology
Environmental health
Kidney disease
Population
Diabetic retinopathy
Empagliflozin
Engineering